Publications by authors named "Max S Topp"

Claim this Profile
E
Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and inferior outcome of CAR-T therapy.
Lukas Scheller, Xiang Zhou, Henry Loeffler-Wirth, Markus Kreuz, Sofie-Katrin Kadel, Max S Topp

Hemasphere· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 Cohort 3.
Tom van Meerten, Marie José Kersten, Gloria Iacoboni, Georg R Hess, Pim G N J Mutsaers, Max S Topp

Blood· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement.
Maximilian J Steinhardt, Christoph Schaefers, Lisa B Leypoldt, Igor-Wolfgang Blau, Marie Harzer, Laura S Topp, Max S Topp

Blood Cancer J· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement.
Maximilian J Steinhardt, Christoph Schaefers, Lisa B Leypoldt, Igor-Wolfgang Blau, Marie Harzer, Laura S Topp, Max S Topp

Blood Cancer J· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3.
Bijal D Shah, Ryan D Cassaday, Jae H Park, Roch Houot, Aaron C Logan, Max S Topp

Leukemia· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study.
Max S Topp, Matthew Matasar, John N Allan, Stephen M Ansell, Jeffrey A Barnes

Blood· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interobserver Agreement Rates on CXCR4-Directed PET/CT in Patients with Marginal Zone Lymphoma.
Rudolf A Werner, Yingjun Zhi, Niklas Dreher, Samuel Samnick, Aleksander Kosmala, Max S Topp

Mol Imaging Biol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia.
Thomas Burmeister, Aeint-Steffen Ströh, Britta Kehden, Heiko Trautmann, Claus Meyer, Max S Topp

Leukemia· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial.
Peter Borchmann, Justin Ferdinandus, Gundolf Schneider, Alden Moccia, Richard Greil, Max S Topp

Lancet· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of debulking therapy on the clinical outcomes of axicabtagene ciloleucel in the treatment of relapsed or refractory large B-cell lymphoma.
Tom van Meerten, John Kuruvilla, Kevin W Song, Catherine Thieblemont, Monique C Minnema, Max S Topp

Am J Cancer Res· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges.
Rudolf Werner, Alexander Haug, Christian Buske, Simon Heidegger, Anna L Illert, Max S Topp

Nuklearmedizin· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Jurriaan Brouwer-Visser, Nathalie Fiaschi, Raquel P Deering, Kamil J Cygan, Darius Scott, Max S Topp

J Immunother Cancer· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemokine receptor-targeted PET/CT provides superior diagnostic performance in newly diagnosed marginal zone lymphoma patients: a head-to-head comparison with [F]FDG.
Aleksander Kosmala, Johannes Duell, Simone Schneid, Sebastian E Serfling, Takahiro Higuchi, Max S Topp

Eur J Nucl Med Mol Imaging· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell-redirecting therapy.
Johannes Duell, Alexander M Leipold, Silke Appenzeller, Viktoria Fuhr, Hilka Rauert-Wunderlich, Max S Topp

Blood· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma.
Michael Fuchs, Anne Sophie Jacob, Helen Kaul, Carsten Kobe, Georg Kuhnert, Max S Topp

Leukemia· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemokine Receptor PET/CT Provides Relevant Staging and Management Changes in Marginal Zone Lymphoma.
Johannes Duell, Andreas K Buck, Philipp E Hartrampf, Wiebke Schlötelburg, Simone Schneid, Max S Topp

J Nucl Med· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enolase 1 of Candida albicans binds human CD4 T cells and modulates naïve and memory responses.
Muhammad Daud, Prasad Dasari, Marion Adelfinger, Daniela Langenhorst, Jasmin Lother, Max S Topp

Eur J Immunol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Sensitivity of Rapid Tests for SARS-CoV-2 Antigen.
Kerstin Knies, Isabell Wagenhäuser, Daniela Hofmann, Vera Rauschenberger, Michael Eisenmann, Max S Topp

Dtsch Arztebl Int· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study.
Maria-Luisa Schubert, Wolfgang A Bethge, Francis A Ayuk, Malte von Bonin, Vladan Vucinic, Max S Topp

Blood Adv· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies.
Dennis A Eichenauer, Ina Bühnen, Christian Baues, Carsten Kobe, Helen Kaul, Max S Topp

Blood· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lymphoma-Sink Effect in Marginal Zone Lymphoma Based on CXCR4-Targeted Molecular Imaging.
Aleksander Kosmala, Simone Seifert, Simone Schneid, Niklas Dreher, Takahiro Higuchi, Max S Topp

Mol Imaging Biol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3.
Bijal D Shah, Ryan D Cassaday, Jae H Park, Roch Houot, Olalekan O Oluwole, Max S Topp

J Immunother Cancer· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
General condition and comorbidity of long-term survivors of adult acute lymphoblastic leukemia.
Nicola Gökbuget, Kristina Ihrig, Michael Stadler, Matthias Stelljes, Ahmet Elmaagacli, Max S Topp

Haematologica· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virus variant-specific clinical performance of SARS coronavirus two rapid antigen tests in point-of-care use, from November 2020 to January 2022.
Isabell Wagenhäuser, Kerstin Knies, Daniela Hofmann, Vera Rauschenberger, Michael Eisenmann, Max S Topp

Clin Microbiol Infect· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study.
Bijal D Shah, Armin Ghobadi, Olalekan O Oluwole, Aaron C Logan, Nicolas Boissel, Max S Topp

J Hematol Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis